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Edited by Hans-Dieter KlenkAbstract The plant cyclotides, the largest known family of
circular proteins, have tightly folded structures and a range of
biological activities that lend themselves to potential pharma-
ceutical and agricultural applications. Based on sequence
homology, they are classiﬁed into the bracelet and M€obius
subfamilies. The bracelet subfamily has previously been shown to
display anti-HIV activity. We show here that a member of the
M€obius subfamily, kalata B1, also exhibits anti-HIV activity
despite extensive sequence diﬀerences between the subfamilies. In
addition, acyclic permutants of kalata B1 displayed no anti-HIV
activity, suggesting that this activity is critically dependent on an
intact circular backbone.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Cyclotide; Cystine knot; Circular protein;
Acyclic permutant1. Introduction
It has become evident in recent years that circular proteins
are present in a wide range of organisms and that backbone
circularization is not restricted to small non-ribosomally syn-
thesized peptides [1,2]. Recently discovered circular proteins
have been isolated from plants, bacteria and even mammals,
with one group forming a particularly large family of related
proteins named the cyclotides [3]. The cyclotides are plant
derived circular proteins containing approximately 30 residues
and three disulﬁde bonds. Approximately 50 sequences have
been published and many more are expected to be discovered
in the near future [3–11].
A range of biological activities have been reported for the
cyclotides, including uterotonic [12], anti-HIV [8] and inhibi-
tion of neurotensin binding [9], but it appears likely that the
peptides are present in plants for defense related purposes
based on their antimicrobial [13] and insecticidal activities [14].
The mechanism of action and the structure–activity relation-
ships associated with these various activities have not been
elucidated.
Analysis of the primary sequences of the cyclotides has re-
vealed the presence of two major subfamilies, namely the* Corresponding author. Fax: +61-7-3346-2029.
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subfamilies is derived from analysis of the three-dimensional
structures that reveal the presence of a cis proline in the
M€obius subfamily that introduces a conceptual twist in the
circular backbone. Although the three-dimensional structures
of only six cyclotides have been reported [3,10,15–18], a highly
conserved framework has emerged, comprising an inhibitor
cystine knot [19] arrangement of the three disulﬁde bonds and
b-sheet secondary structure as shown in Fig. 1. This structural
motif has been termed the ‘‘cyclic cystine knot’’ (CCK) and
appears to confer extreme structural stability to the molecules
containing it [3]. A small region of helix is present in some
members of the bracelet subfamily.
The sequences of selected members of both subfamilies
[8,10,20] are shown in Fig. 1 together with their disulﬁde
connectivity [17,21–23]. The six backbone loops between the
six cysteine residues have varying degrees of conservation both
within and between the subfamilies. The most highly conserved
are loops 1 and 4, which comprise backbone segments that are
directly involved in the cystine knot motif. We have previously
shown that breaking the backbone in these loops prevents
folding into a native-like conformation. By contrast, a break in
the backbone in any of the other four loops leads to acyclic
permutants that display a native fold, albeit without a cyclic
backbone [24].
The cyclotides have potential applications in the pharma-
ceutical and agricultural ﬁelds based on their intrinsic activi-
ties. In particular, the worldwide AIDS epidemic has
intensiﬁed interest in identifying naturally occurring antiviral
molecules [25]. Several cyclotides have been reported to have
anti-HIV activity [6–8,26] and indeed these cyclotides were ﬁrst
identiﬁed in screening programs directed towards such activity.
Furthermore, their potent insecticidal activity suggests that the
cyclotides may be useful as ‘‘natural’’ insecticides if applied to
crop plants. Given that the cyclotides are gene encoded, it may
be possible to produce transgenic plants engineered to have
built in resistance toHelicoverpa and related pests, much in the
same way as the Bacillus thuringiensis toxin has been used to
protect corn, cotton and soy beans [27]. In addition to making
use of their intrinsic activity, the stable framework of the cy-
clotides might also prove useful as a molecular scaﬀold onto
which novel bioactivities may be grafted [28,29].
To realize the potential of cyclotides, a thorough analysis of
their structure–activity relationships is required. The natural
sequence variation observed in the cyclotides provides a meansblished by Elsevier B.V. All rights reserved.
Fig. 1. Amino acid sequences of cyclotides tested for anti-HIV activity. (A) The six-cysteine residues are highlighted in bold and the disulﬁde
connectivity is shown by lines connecting the cysteine residues. The six backbone loops between the cysteine residues are labeled loops 1–6. The
circular backbone is represented by a line connecting loops 1 and 6. The proline in loop 5 of kalata B1 is boxed to highlight the fact that the no-
menclature for the M€obius subfamily is based on this proline being in a cis conformation. (B) The three-dimensional structure of the prototypic
cyclotide kalata B1 [pdb code-1NB1]. The disulﬁde bonds are shown with gray lines and the loops are labeled 1–6. The location of the backbone twist
due to a cis-Pro peptide bond in the M€obius subfamily is highlighted by a curved arrow in loop 5.
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known cyclotides have been tested in a wide range of assays.
Selected members of both families have been tested in anti-
microbial assays and the greater number of positively charged
residues in the bracelet cyclotides has been suggested to result
in the broader spectrum of antimicrobial activity compared to
kalata B1, a member of the M€obius subfamily [13]. So far,
anti-HIV activity has only been demonstrated for bracelet
cyclotides [6–8].
To address the question of whether anti-HIV activity is
speciﬁc to the bracelet cyclotides, we have examined the anti-
HIV activity of kalata B1, the prototypic member of the
M€obius subfamily. We show that despite its reduced cationic
character, kalata B1 also exhibits anti-HIV activity. Further-
more, acyclic permutants of kalata B1 (i.e., molecules with the
backbone opened in each of the six loops between the cysteine
residues as shown in Fig. 2) were inactive, indicating that anti-
HIV activity is critically dependent on the presence of an intact
cyclic backbone.Fig. 2. Acyclic permutants of kalata B1 in which the backbone is
opened in each of the six loops. The peptides are numbered according
to the backbone loop that is broken in the acyclic derivative. The in-
troduced N- and C-termini of the acyclic permutants are shown un-
derneath the native sequence, with the broad black lines indicating
where the native sequence is retained. In most cases, a few residues of
the original circular peptide sequence were truncated at the break sites.
Permutants 2, 3 5, 6a and 6b folded in native-like conformations and
were analyzed for anti-HIV activity.2. Materials and methods
Synthesis of kalata B1 and acyclic permutants – Kalata B1 and its
acyclic permutants were synthesized as previously described [24,30].
Brieﬂy, peptides were assembled using manual solid phase peptide
synthesis with Boc chemistry on a 0.5 mmole scale. MBHA or PAM
resin was used (Applied Biosystems, Foster City, CA) and amino acids
added to the resin using HBTU with in situ neutralization [31]. N-terminal acetylation was performed on resin for one of the permutants
with a vast excess of acetic anhydride and DIEA in DMF. Cleavage of
the peptide from the resin was achieved using hydrogen ﬂuoride (HF)
with cresol and thiocresol as scavengers (HF:cresol:thiocresol; 9:1:1 v/
v). The reaction was allowed to proceed at )5 to 0 C for 1 h. Fol-
lowing cleavage, the peptides were dissolved in 50% acetonitrile, 0.1%
TFA and lyophilized. The crude, reduced peptides were puriﬁed using
preparative reverse-phase HPLC (RP-HPLC) on a Vydac C18 column.
Gradients of 0.1% aqueous TFA and 90% acetonitrile/0.09% TFA
were employed with a ﬂow rate of 8 ml/min and the eluant monitored
at 230 nm. These conditions were used in the subsequent puriﬁcation
N.L. Daly et al. / FEBS Letters 574 (2004) 69–72 71steps. Mass analysis was performed on a Sciex (Thornhill, Ontario)
triple quadrupole mass spectrometer using electrospray sample
ionization.
Disulﬁde formation – Oxidation reactions on the permutants were
performed using the optimum conditions established for the cyclic
peptide [30]. The puriﬁed reduced peptides were dissolved in 50% 2-
propanol, in the presence of 1–10 mM reduced glutathione in 0.1 M
ammonium bicarbonate (pH 8.5). The reactions were left at room
temperature for 24 h. The pH was lowered with TFA prior to puriﬁ-
cation with RP-HPLC.
Anti-HIV activity assays – An in vitro XTT-based anti-HIV assay
was used as described previously [32] to examine the eﬀect of kalata B1
and its acyclic permutants on virus-induced cell killing in HIV-infected
cultures.3. Results and discussion
In the current study, we show for the ﬁrst time that a
member of the M€obius subfamily of cyclotides exhibits anti-
HIV activity. Kalata B1 was synthesized and the disulﬁde
bonds formed as previously described [30]. The synthetic
peptide has been shown by NMR spectroscopy to be identical
to the native form [30]. Anti-HIV assays were performed on
synthetic kalata B1 with the highest concentration of sample
tested being 3500 nM. Kalata B1 eﬀectively inhibited the cy-
topathic eﬀects of HIV-1 infection in cultured human T-lym-
phoblast (CEM-SS) cells. The antiviral cytoprotective
concentration (EC50) of synthetic kalata B1 is approximately
140 nM, while the cytotoxic concentration (IC50) was greater
than 3500 nM. Table 1 summarizes the results and compares
them with data for other cyclotides.
The level of activity displayed by kalata B1 is comparable to
the other cyclotides that have been tested, including circulins
A–F [7,8] cycloviolins A–D [6] and palicourein [26]. These
peptides displayed EC50 values of 40–275 nM, depending on
the type of cell line used (Table 1). Interestingly, the IC50 of
kalata B1 was >3500 nM, whereas IC50’s of 500–1500 nM
were observed for the circulins, cycloviolins and palicourein
[6–8]. Thus, the ‘‘therapeutic index’’ of kalata B1 is substan-
tially higher than other cyclotides. There is a relatively high
degree of sequence similarity between the circulins and cycl-
oviolins. However, cycloviolin B diverges from the other se-
quences with signiﬁcant variations in loops 2 and 5, as shown
in Fig. 1. Kalata B1 also diﬀers signiﬁcantly from the circulins
and cycloviolins, particularly in loops 2, 3 and 5. Given the
similarity in the assay results for the various cyclotides tested,
including those coming from diﬀerent subfamilies, it appears
that sequence variation does not signiﬁcantly inﬂuence the
anti-HIV activity.Table 1
Anti-HIV activity of cyclotides
Peptide EC50
a IC50
b Reference
Kalata B1 140 nM >3500 nM This study
Acyclic permutants
of kalata B1
No activity No activity This study
Circulins A–F 40–275 nM 500 nMc [7,8]
Cycloviolins A–D 130 nM 560 nM [6]
Palicourein 100 nM 1500 nM [26]
a Values for HIV-infected cell lines.
bValues for uninfected cell lines.
c IC50 values are for circulins A and B.One of the most signiﬁcant sequence variations observed
between the bracelet and M€obius subfamilies is the presence of
a larger number of cationic residues in the bracelet family. This
feature has been highlighted in a previous study on the anti-
microbial activity of cyclotides [13] in which the arginine res-
idue of both kalata B1 and circulin A was modiﬁed. The study
suggested that at least one cationic residue is required for
electrostatic interactions with bacterial surfaces for activity
[13]. This observation is consistent with the current analysis
because kalata B1 and cycloviolin B, both of which contain
a single positive charge, display anti-HIV activity. It will be
of interest to determine the activity of mutants not contain-
ing this positive charge or of those with additional charges
included in the sequence. Alanine mutagenesis studies will
provide a better understanding of the critical residues for
activity.
Acyclic permutants of kalata B1 were also tested in the anti-
HIV assay to examine the eﬀect of opening the backbone on
this activity. Acyclic permutants involving backbone breaks in
loops 2, 3, 5, and 6 were used in the study as they retained the
native fold [24]. By contrast, opening the backbone in loops 1
and 4 prevented folding into the native conformation and so
these derivatives could not be studied. None of the acyclic
permutants tested, i.e., compounds (2), (3), (5), (6a), and (6b)
in Fig. 2, were active at concentrations of 3.5 to 20 lM. All
of the permutants, with the exception of (2), were synthesized
with C-terminal amides and thus negative charges were not
introduced. Permutant (3) was also synthesized with an acet-
ylated N-terminus, but this variant still did not display anti-
HIV activity, indicating that the lack of anti-HIV activity is
not due to the introduction of a positive charge in the per-
mutant. The lack of activity of the acyclic permutants suggests
that the critical residues for activity are not localized to one
region of the molecule. Although the overall native fold is
retained in the acyclic permutants as evidenced by a chemical
shift analysis and determination of the three-dimensional
structure of one of the loop 6 analogs [33], diﬀerences have
been observed in the amide exchange rates [24]. Speciﬁcally, an
increase in the amide exchange rates was observed for the
acyclic permutants relative to the native, cyclic peptide, indi-
cating increased accessibility of solvent to the hydrogen bond
network of the cyclotides. In turn, this is likely associated with
increased ﬂexibility and a decrease in stability upon opening
the circular backbone. It is possible that such diﬀerences in
backbone ‘‘breathing’’ motions are related to the lack of anti-
HIV activity of the acyclic permutants. However, further
mutagenesis studies are required to conﬁrm a role for the
circular backbone and discern why the activity does not appear
to be localized.
The trends in anti-HIV activity seen in the current study
correlate well with previous results where the native peptide
displayed hemolytic activity but not the acyclic permutants
[24]. It is possible that a common mechanism is involved in
both these activities, although further analysis is required to
elucidate the mechanism. Given the range of activities dis-
played by the cyclotides, it appears likely that their mode of
action may involve some type of membrane disruption.
In summary, we have shown that anti-HIV activity is not
restricted to the bracelet subfamily of the cyclotides as a
member of the M€obius subfamily also displays it. The se-
quence variation between the subfamilies does not appear to
inﬂuence the level of activity, suggesting that the overall fold is
72 N.L. Daly et al. / FEBS Letters 574 (2004) 69–72important for activity rather than individual residues. How-
ever, the dynamics of the backbone may also play a role, as
acyclic permutants that are structurally similar to the native
peptide, but are potentially more ﬂexible, do not have anti-
HIV activity. The fact that kalata B1 has similar anti-HIV
activity, but decreased cytotoxicity suggests that it may be a
more promising lead in anti-HIV therapy than previously
tested cyclotides. Further testing of a range of naturally oc-
curring cyclotides and synthetic mutants will provide valuable
information on the structure–activity relationships of this
fascinating family of macrocyclic peptides.
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